Prostaglandins & other lipid mediators最新文献

{"title":"Advances and challenges in lipid droplet isolation from animal tissues and cells","authors":"Yangli Pei,&nbsp;Siyu Wu,&nbsp;Zheng Feng","doi":"10.1016/j.prostaglandins.2025.106996","DOIUrl":"10.1016/j.prostaglandins.2025.106996","url":null,"abstract":"<div><div>Lipid droplets (LDs) are essential intracellular organelles involved in lipid storage and metabolism, playing critical roles in various cellular processes and diseases. Researchers require efficiently isolate and analyze LDs to understand lipid metabolism and related pathologies. This review summarizes recent advances in LD isolation methods, including traditional techniques such as centrifugation and density gradient centrifugation, as well as emerging technologies like automated and high-throughput approaches. We explore the applications of these methods in lipid metabolism research and discuss the challenges faced by current isolation techniques. Future directions, including automation, single-cell analysis, and integration with advanced analytical tools, are also highlighted to provide insights for the next generation of LD research.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"178 ","pages":"Article 106996"},"PeriodicalIF":2.5,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143923469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protection of lutein against the toxic effect of cisplatin on liver in male rat","authors":"Ibrahim Aktas ,&nbsp;Fatih Mehmet Gur ,&nbsp;Sedat BILGIÇ","doi":"10.1016/j.prostaglandins.2025.106995","DOIUrl":"10.1016/j.prostaglandins.2025.106995","url":null,"abstract":"<div><h3>Objective</h3><div>A major challenge in cancer treatment is the detrimental effects of anticancer drugs on healthy organs and tissues. This study aims to investigate the protective effects of Lutein (LU) against Cisplatin (CT)-induced toxicity in rat liver, utilizing biochemical and histopathological assessments.</div></div><div><h3>Methods</h3><div>In this study, CT was administered intraperitoneally (i.p.) at a dose of 10 mg/kg, while LU was administered orally at a dose of 100 mg/kg. The experiment was conducted over a 7-day period with 28 male Sprague-Dawley rats (weighing 210–265 g, aged 11 weeks), divided into four groups (n = 7): Control, LU, CT, and CT + LU.</div></div><div><h3>Results</h3><div>CT-induced liver injury was identified as a dose-limiting side effect of CT. Compared to the CT group, the CT + LU group exhibited a significant decrease in malondialdehyde (MDA) levels and an increase in superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH) levels. In the CT group, a significant increase in the levels of gamma-glutamyl transferase (GGT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lactate dehydrogenase (LDH) was observed, compared to the control group (p &lt; 0.05). When comparing the CT + LU group with the CT group, a significant reduction in the levels of GGT, ALT, AST, and LDH was observed (p &lt; 0.05). Histopathological analysis revealed liver damage in the CT group, characterized by leukocyte infiltration, sinusoidal dilatation, Councilman body formation, and hepatocellular degeneration and steatosis. In contrast, the CT + LU group exhibited only mild sinusoidal dilatation, with no other significant lesions. Immunohistochemical analysis showed positive staining for tumour necrosis factor-alpha (TNF-α) and caspase-3 in the liver tissue of CT group rats, which was significantly reduced in the CT + LU group. The staining pattern in the CT + LU group was similar to that of the control and LU groups.</div></div><div><h3>Conclusion</h3><div>The results of this study suggest that LU mitigates oxidative stress, enhances antioxidant defences, and supports liver function. Furthermore, LU demonstrates a protective effect against CT-induced liver damage, indicating its potential as a pharmacological agent for preventing CT-induced hepatic injury.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"178 ","pages":"Article 106995"},"PeriodicalIF":2.5,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143874115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of highly bioavailable forms of curcumin on lipoprotein(a) plasma levels: A systematic review and meta-analysis of randomized clinical studies","authors":"Federica Fogacci ,&nbsp;Ashot Avagimyan ,&nbsp;Arturo Cesaro ,&nbsp;Marco Bernardi ,&nbsp;Francesco Perone ,&nbsp;Marina Giovannini ,&nbsp;Arrigo Francesco Giuseppe Cicero","doi":"10.1016/j.prostaglandins.2025.106994","DOIUrl":"10.1016/j.prostaglandins.2025.106994","url":null,"abstract":"<div><div>Curcumin is a bioactive compound derived from the rhizome of <em>Curcuma longa</em> (turmeric) that has garnered increasing attention for its potential health benefits. However, its use in clinical practice is limited due to its generally poor bioavailability. This issue can be overcome using novel delivery systems that enhance curcumin’s solubility, extend its residence time in plasma, improve its pharmacokinetic profile, and increase its cellular uptake. Novel curcumin formulations with improved bioavailability have been suggested to elevate plasma concentrations of lipoprotein(a) (Lp(a)), but there is no definitive evidence of a causal relationship. To address this, a systematic literature search was conducted in multiple electronic databases to identify relevant randomized placebo-controlled clinical studies published without a time limit. A meta-analysis of data suggested that dietary supplementation with highly bioavailable forms of curcumin significantly reduces Lp(a) levels [Standardized Mean Difference (SMD)= -0.96 (95 % Confidence Interval (CI): −1.82, −0.11)]. The effect size was robust in the leave-one-out sensitivity analysis and was not primarily driven by any single study. Of course, the clinical significance of this observation should be more thoroughly evaluated in longer-term trials, where the combined metabolic and anti-inflammatory effects of curcumin have vascular protective effects.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"178 ","pages":"Article 106994"},"PeriodicalIF":2.5,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143848655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oxysterols, age-related-diseases and nutritherapy: Focus on 7-ketocholesterol and 7β-hydroxycholesterol","authors":"Anne Vejux ,&nbsp;Imen Ghzaiel ,&nbsp;John J. Mackrill ,&nbsp;Irundika H.K. Dias ,&nbsp;Leila Rezig ,&nbsp;Mohamed Ksila ,&nbsp;Amira Zarrouk ,&nbsp;Thomas Nury ,&nbsp;Fatiha Brahmi ,&nbsp;Adil El Midaoui ,&nbsp;Smail Meziane ,&nbsp;Atanas G. Atanasov ,&nbsp;Sonia Hammami ,&nbsp;Norbert Latruffe ,&nbsp;Pierre Jouanny ,&nbsp;Gérard Lizard","doi":"10.1016/j.prostaglandins.2025.106993","DOIUrl":"10.1016/j.prostaglandins.2025.106993","url":null,"abstract":"<div><div>Age-related diseases are often associated with a disruption of RedOx balance that can lead to lipid peroxidation with the formation of oxysterols, especially those oxidized on carbon-7: 7-ketocholesterol (also known as 7-oxo-cholesterol) and 7β-hydroxycholesterol. Like cholesterol, these oxysterols have 27 carbons, they are composed of a sterane nucleus and have a hydroxyl function in position 3. The oxysterols 7-ketocholesterol and 7β-hydroxycholesterol are mainly formed by cholesterol autoxidation and are biomarkers of oxidative stress. These two oxysterols are frequently found at increased levels in the biological fluids (plasma, cerebrospinal fluid), tissues and/or organs (arterial wall, retina, brain) of patients with age-related diseases, especially cardiovascular diseases, neurodegenerative diseases (mainly Alzheimer’s disease), ocular diseases (cataract, age-related macular degeneration), and sarcopenia. Depending on the cell type considered, 7-ketocholesterol and 7β-hydroxycholesterol induce either caspase- dependent or -independent types of cell death associated with mitochondrial and peroxisomal dysfunctions, autophagy and oxidative stress. The caspase dependent type of cell death associated with oxidative stress and autophagy is defined as oxiapoptophagy. These two oxysterols are also inducers of inflammation. These biological features associated with the toxicity of 7-ketocholesterol, and 7β-hydroxycholesterol are often observed in patients with age-related diseases, suggesting an involvement of these oxysterols in the pathophysiology of these disorders. The cytotoxic effects of 7-ketocholesterol and 7β-hydroxycholesterol are counteracted on different cell models by representative nutrients of the Mediterranean diet: ω3 and ω9 fatty acids, polyphenols, and tocopherols. There are also evidences, mainly in cardiovascular diseases, of the benefits of α-tocopherol and phenolic compounds. These <em>in vitro</em> and <em>in vivo</em> observations on 7-ketocholesterol and 7β-hydroxycholesterol, which are frequently increased in age-related diseases, reinforce the interest of nutritherapeutic treatments to prevent and/or cure age-related diseases currently without effective therapies.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"178 ","pages":"Article 106993"},"PeriodicalIF":2.5,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143855233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An updated systematic review and meta-analysis of pomegranate consumption on lipid profile","authors":"Wengong Cheng ,&nbsp;Kaiqin Liang ,&nbsp;Aiqiong Huang","doi":"10.1016/j.prostaglandins.2025.106992","DOIUrl":"10.1016/j.prostaglandins.2025.106992","url":null,"abstract":"<div><div>Pomegranate, rich in bioactive compounds such as polyphenols and flavonoids, has been studied for its potential lipid-modulating effects, yet evidence remains inconsistent. This systematic review and meta-analysis aimed to evaluate the impact of pomegranate consumption on plasma lipid profiles by synthesizing data from randomized controlled trials (RCTs). Following PRISMA guidelines, 37 RCTs (n = 2695 participants) were included after searching Scopus and MEDLINE databases. Studies assessed pomegranate products (juice, extract, seed oil) administered orally for ≥ 7 days, with lipid parameters, including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG) as outcomes. Data were pooled using RevMan 5.3 with random-effects models. Results indicated that pomegranate intake significantly increased HDL-C levels (mean difference: 2.50 mg/dL, 95 % CI: 1.00–4.00, <em>p</em> &lt; 0.05), while no significant changes were observed in TC, LDL-C, or TG. Subgroup analyses revealed pronounced HDL-C elevation in non-alcoholic fatty liver disease (NAFLD) patients, health participants and interventions lasting ≥ 8 weeks. Heterogeneity across studies was attributed to variations in intervention duration, dosage forms, and participant characteristics. Publication bias was nonsignificant (Egger’s test, <em>p</em> &gt; 0.05). These findings suggest that pomegranate supplementation may improve HDL-C, potentially through modulation of HDL-associated enzymes like paraoxonase. However, further large-scale, long-term RCTs are warranted to confirm these effects and explore synergistic benefits with standard lipid-lowering therapies.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"178 ","pages":"Article 106992"},"PeriodicalIF":2.5,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143842911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of walnut consumption on biomarkers of oxidative stress: A systematic review and meta-analysis of randomized controlled trials","authors":"Vali Musazadeh ,&nbsp;Mahsa Mahmoudinezhad ,&nbsp;Niloofar Hamidi ,&nbsp;Maryam Falahatzadeh ,&nbsp;Farzad Shidfar","doi":"10.1016/j.prostaglandins.2025.106986","DOIUrl":"10.1016/j.prostaglandins.2025.106986","url":null,"abstract":"<div><div>Oxidative stress is caused by an imbalance between accumulation and production of oxygen reactive species (ROS) in tissues and cells and play a key role in many diseases. This systematic review and meta-analysis of randomized controlled trials (RCTs) was performed to analyze the effects of walnut consumption on biomarkers of oxidative stress. Databases including PubMed, Scopus, Embase and Web of science were searched until November 30th, 2024. Data were subjected to meta-analysis using a random effects model to examine the effect sizes of the pooled results. Four studies were identified eligible to be included in current meta-analysis. Walnut consumption resulted in a significant increase in catalase activity (CAT) (WMD: 42.20; 95 % CI: 34.28, 50.11). Walnut consumption did not affect other biomarkers of oxidative stress such as lipid peroxidation (LPO), reduced glutathione (GSH), oxidized glutathione (GSSG) and oxygen radical absorbance capacity (ORAC). Overall, this meta-analysis demonstrated walnut consumption increase CAT, but did not affect other biomarkers of oxidative stress. This suggests that walnut may have played an indirect and mild role in health. However, due to the limited number of studies, further investigations is suggested in this regard.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"178 ","pages":"Article 106986"},"PeriodicalIF":2.5,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143768314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1RAs regulate lipid metabolism and induce autophagy through AMPK/SIRT1 pathway to improve NAFLD","authors":"Qiang Zhang ,&nbsp;Jingyuan Wang ,&nbsp;Xiaojin Hu ,&nbsp;Wei Lu ,&nbsp;Yang Cao ,&nbsp;Chunyan Niu ,&nbsp;Hongqin Yue","doi":"10.1016/j.prostaglandins.2025.106987","DOIUrl":"10.1016/j.prostaglandins.2025.106987","url":null,"abstract":"<div><h3>Background</h3><div>Non-alcoholic fatty liver disease (NAFLD) is a leading cause of cirrhosis and a major risk factor for hepatocellular carcinoma and liver-related death. Diabetes medications have been studied as potential treatments for NAFLD. Glucagon-like peptide-1 agonists (GLP-1RAs) have been rarely reported in the treatment of NAFLD alone as an anti-diabetic drug, and its specific mechanism of action is unknown. We investigated whether the therapeutic effect of liraglutide (LRG, a representative drug of GLP-1RAs) on hepatic steatosis is related to regulating lipid metabolism and enhancing autophagy in the hepatocytes.</div></div><div><h3>Methods</h3><div>We examined the effect of LRG on fat accumulation in fatty hepatocytes, and discussed its effects on enzymes related to lipid metabolism and autophagy. Meanwhile, knockdown of SIRT1 in free fatty acids(FFA)-treated cells was used to detected the influence of LRG on lipid metabolism and autophagy by regulating of AMPK/SIRT1 signaling.</div></div><div><h3>Results</h3><div>Our findings showed that free fatty acids (FFA) induced hepatocyte steatosis, which was significantly reversed by LRG. Meanwhile, LRG significantly regulated the expression of hepatocyte lipogenesis and cytosolic lipolysis-related proteins (FAS, ACC1, ATGL, HSL, LAL). Furthermore, LRG enhanced FFA-induced suppression of autophagy and SIRT1 expression, reducing intracellular lipid accumulation. It is evident that LRG regulates lipid metabolism and induces autophagy in an (AMPK)-dependent manner. Moreover, SIRT1 knockdown inhibited the autophagy-inducing and lipid-lowering effects of LRG.</div></div><div><h3>Conclusion</h3><div>GLP-1RAs may lower hepatic steatosis by regulating lipid metabolism and enhancing autophagy in an AMPK/SIRT1-dependent manner, providing a new target for the treatment of NAFLD.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"178 ","pages":"Article 106987"},"PeriodicalIF":2.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143768313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of statin use on blood pressure and other hypertension-related outcome indicators in hypertensive patients: A systematic review and meta-analysis","authors":"Zhaohan Chu ,&nbsp;Wei Yue ,&nbsp;Qingqing Mu ,&nbsp;Dong Xu ,&nbsp;Zexu Chang ,&nbsp;Mengke Liang ,&nbsp;Yixiao Geng ,&nbsp;Ping Ding","doi":"10.1016/j.prostaglandins.2025.106991","DOIUrl":"10.1016/j.prostaglandins.2025.106991","url":null,"abstract":"<div><h3>Aims</h3><div>This meta-analysis delved into the impact of statin therapy, both as a monotherapy and in conjunction with antihypertensive medications, on blood pressure levels and outcomes pertinent to hypertension.</div></div><div><h3>Methods</h3><div>We searched the PubMed, EMBASE, and Cochrane databases for studies published before October 1 2023. Studies designed as cohort studies or randomized controlled trials and investigating the effects of single use of statin or its combined use with other antihypertensive therapy were included. Authors extracted the data independently and differences were decided through discussion. Random-effects model was used to evaluate the merged outcomes. Due to the high heterogeneity of the HDL-C group, we performed subgroup analysis according to the type of statin. To assess the robustness and potential publication bias of our findings, we utilized sensitivity analysis, Egger’s test, and funnel plots.</div></div><div><h3>Results</h3><div>23 trials were included in this meta-analysis. The primary outcomes revealed that administering statins did not significantly impact the systolic pressure (SBP) of hypertensive patients (MD, −1.77; 95 % CI, −4.82–1.27). —The promoted effect of statin treatment on diastolic pressure (DBP) in hypertensive patients was found (MD, −1.87; 95 % CI, −3.72 –-0.01). The secondary outcomes revealed that the use of statins resulted in a significant reduction in low-density lipoprotein (LDL-C), while significantly increasing high-density lipoprotein (HDL-C) in hypertensive patients.</div></div><div><h3>Conclusion</h3><div>Statin use did not modulate SBP and DBP of patients with hypertension, but SBP was decreased in the rosuvastatin or pravastatin subgroup, while DBP was decreased in the simvastatin or pravastatin subgroup. Statin treatment reduced LDL-C, increased HDL-C, and reduced the incidence of cardiovascular events and mortality compared to control groups.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"178 ","pages":"Article 106991"},"PeriodicalIF":2.5,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143773212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decreased plasma lipoxin A4, resolvin D1, protectin D1 are correlated with the complexity and prognosis of coronary heart disease: A retrospective cohort study","authors":"Yun-fei Wang ,&nbsp;Xue-tao Zhu ,&nbsp;Ze-ping Hu","doi":"10.1016/j.prostaglandins.2025.106990","DOIUrl":"10.1016/j.prostaglandins.2025.106990","url":null,"abstract":"<div><div>This study aimed to assess the predictive capacity of specialized pro-resolving mediators (SPMs) regarding the complexity and prognosis of coronary heart disease (CHD). Total of 602 CHD patients were included in this study and categorized into low-risk, medium-risk, and high-risk groups based on the Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) score. Follow-up was conducted for two years, during which patients were dichotomized into poor and good prognosis groups. Additionally, twenty healthy controls were incorporated. Plasma concentrations of lipoxin A4 (LXA4), resolvin D1 (RvD1), protectin D1 (PD1), C-reactive protein (CRP), interleukin-6 (IL-6), and IL-10 were quantified. Plasma LXA4, RvD1, PD1, and the ratios LXA4/IL-6, RvD1/IL-6, PD1/IL-6 exhibited a gradual decrease across control, low-risk, medium-risk, and high-risk groups and exhibited a negative correlation with the SYNTAX score. Spearman’s correlation analysis revealed negative correlations between plasma LXA4, RvD1, PD1, and both CRP and IL-6, and positive correlations with IL-10. Multiple linear regression models demonstrated negative associations between plasma LXA4, RvD1, PD1, and SYNTAX score. Moreover, both univariate and multivariate binary logistic regression analyses identified plasma LXA4, RvD1, and PD1 as protective factors against medium/high-risk SYNTAX score categorization. In the poor prognosis group, plasma PD1 was reduced at short-term follow-up, and the ratios LXA4/IL-6, RvD1/IL-6, PD1/IL-6 were reduced at long-term follow-up. Plasma LXA4, RvD1, and PD1 demonstrated negative correlations with CHD complexity and potentially served as protective factors against CHD. Plasma PD1 provided predictive value for short-term prognosis, while the ratios LXA4/IL-6, RvD1/IL-6, PD1/IL-6 were indicative for long-term prognosis.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"178 ","pages":"Article 106990"},"PeriodicalIF":2.5,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"E2F7 upregulates MCM4 and fatty acid metabolism to advance lung adenocarcinoma metastasis","authors":"WuAsen Tang ,&nbsp;Deming Zhang ,&nbsp;Di Liu,&nbsp;Zikang Liu,&nbsp;Kuang Xiao,&nbsp;Chenggang Lei,&nbsp;Yalun Yang,&nbsp;Qian Zhou,&nbsp;Xianghui Wang","doi":"10.1016/j.prostaglandins.2025.106988","DOIUrl":"10.1016/j.prostaglandins.2025.106988","url":null,"abstract":"<div><h3>Background</h3><div>MCM4, a key protein in MCM, is frequently overexpressed in cancers, but its specific role in lung adenocarcinoma (LUAD) metastasis is unclear.</div></div><div><h3>Methods</h3><div>Bioinformatics revealed the mRNA expression pattern of MCM4 in LUAD, which we confirmed in both normal lung epithelial and adenocarcinoma cell lines using qRT-PCR and western blot (WB). Cellular proliferation was gauged by cell counting kit-8 and colony formation assays, and the expression of epithelial-mesenchymal transition markers along with fatty acid synthase (FASN) was probed via WB. We employed Transwell to assess cellular migration and invasion, and utilized kits for quantifying intracellular triglycerides and phospholipids. Bioinformatics identified E2F7 as a potential transcriptional regulator of MCM4, prompting us to explore its relationship with MCM4, including predicted binding sites and E2F7 mRNA expression in LUAD. Chromatin immunoprecipitation and dual-luciferase reporter assays were conducted to validate the regulatory effects of E2F7 on MCM4.</div></div><div><h3>Results</h3><div>MCM4 was found to be overexpressed in LUAD, and its knockdown inhibited cancer cell proliferation, migration, invasion, and metastasis, along with decreased FASN expression and declined levels of triglycerides and phospholipids within cells. Mechanistically, E2F7 transcriptionally activated MCM4, regulating fatty acid metabolism and promoting LUAD progression and metastasis.</div></div><div><h3>Conclusion</h3><div>Our study elucidates the mechanism by which E2F7 transcriptionally controls MCM4 to activate fatty acid metabolism, fueling LUAD metastasis. These discoveries emphasize the pivotal function of lipid metabolism in LUAD development and suggests new therapeutic targets for LUAD treatment.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"178 ","pages":"Article 106988"},"PeriodicalIF":2.5,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}